Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Next-Generation Osteoarthritis Candidate Hylastan Found Not Superior To Steroids

This article was originally published in The Pink Sheet Daily

Executive Summary

Failed therapy is now on the back burner, as focus turns to approval and introduction of single-treatment viscosupplementation product Synvisc-One, company tells “The Pink Sheet” DAILY.

You may also be interested in...



Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies

“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.

Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies

“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.

Bioenvision Investors Unhappy With Genzyme Acquisition Deal

Web site urges shareholders to reject Genzyme’s “lowball” tender offer.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel